Informations générales (source: ClinicalTrials.gov)

NCT01520844 En recrutement IDF
Multicentric Cohort of HIV Patient With Extrem Profil (CODEX)
Interventional
  • Infections à VIH
N/A
ANRS, Emerging Infectious Diseases (Voir sur ClinicalTrials)
février 2012
septembre 2023
28 décembre 2024
A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CHI DE CRETEIL Isabelle DELACROIX-SZMANIA En recrutement IDF 29/03/2024 01:27:32  Contacter
HOPITAL NOVO BLUM En recrutement IDF 04/12/2024 13:04:45  Contacter
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
HOPITAL FOCH vendredi 11 mars 2022 Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Lambotte - Kremlin Bicetre - France En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Patient infected with HIV-1 and not co-infected with HIV-2

- Age ≥ 18 at enrollment

- Able to give written consent

- Covered by French Social Security

- accept the constraints imposed by the study

- without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of
viral load after antiretroviral treatment interruption in PTC group

ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above
600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years regardless of the viral load
in the absence of antiretroviral treatment

HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the
last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the
absence of antiretroviral treatment

ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater
than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years and with the last 5 viral
loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy.

PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of
antiretroviral therapy. Treatment started during the primary infection (as defined by
symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an
incomplete P24-positive Western blot) or during the chronic phase of infection, and
maintained for at least 12 months in both cases. Control of viral load after
antiretroviral treatment interruption: patients must have at least two available viral
load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL
for 12 months or more after stopping antiretroviral therapy, with the possible exception
of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at
least one month apart from the blip; in this case at least three viral load assays will
be required). The last plasma viral load value at the time of inclusion must always be
<400 copies/mL



Under protection(saving) of justice